Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Kosmider O, Passet M, Santini V, Platzbecker U, Andrieu V, Zini G, Beyne-Rauzy O, Guerci A, Masala E, Balleari E, Bulycheva E, Dreyfus F, Fenaux P, Fontenay M, Park S; GFM, FISM AND D-MDS.
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
